Sharma P, Weston A P, Morales T, Topalovski M, Mayo M S, Sampliner R E
Division of Gastroenterology, University of Kansas, VA Medical Center, Kansas City, Missouri 64128, USA.
Gut. 2000 Jan;46(1):9-13. doi: 10.1136/gut.46.1.9.
Biopsy specimens obtained from the gastro-oesophageal junction can reveal intestinal metaplasia in patients presenting for routine upper endoscopy. The site of biopsy may play a critical role in determining the dysplasia risk of a patient.
To evaluate prospectively the dysplasia risk in patients with intestinal metaplasia of the distal oesophagus or within the gastric cardia.
Patients with short segment Barrett's oesophagus (SSBO) and cardia intestinal metaplasia (CIM) were followed prospectively.
177 patients with SSBO were identified (mean age 62 years, range 38-82; 91% whites). Twenty prevalence cases of dysplasia in SSBO were detected: 17 low grade dysplasia (LGD), three high grade dysplasia (HGD). Seventy six patients with CIM were identified (mean age 67 years, range 37-81; 81% whites). A single prevalence case of LGD in CIM was detected. During follow up of 78 SSBO and 34 CIM patients, dysplasia developed in nine (seven LGD, two HGD) with SSBO and in one (LGD) with CIM. There were significant differences between the two groups with respect to age, ethnicity, dysplasia prevalence, and incidence. Time to dysplasia progression was significantly longer in CIM compared with SSBO patients. Of the five patients with SSBO and HGD, one developed adenocarcinoma of the oesophagus on follow up. No HGD or cancers have been detected over this time period in CIM patients.
The dysplasia risk is significantly greater in SSBO than in CIM patients, indicating two potentially different clinical processes. Future studies should separate SSBO from CIM in order to enhance the understanding of the pathophysiology and malignant potential of each entity.
在接受常规上消化道内镜检查的患者中,取自胃食管交界处的活检标本可发现肠化生。活检部位可能在确定患者的发育异常风险中起关键作用。
前瞻性评估远端食管或贲门部肠化生患者的发育异常风险。
对短段Barrett食管(SSBO)和贲门肠化生(CIM)患者进行前瞻性随访。
共识别出177例SSBO患者(平均年龄62岁,范围38 - 82岁;91%为白人)。在SSBO中检测到20例发育异常病例:17例低级别发育异常(LGD),3例高级别发育异常(HGD)。共识别出76例CIM患者(平均年龄67岁,范围37 - 81岁;81%为白人)。在CIM中检测到1例LGD患病率病例。在对78例SSBO和34例CIM患者的随访中,SSBO中有9例(7例LGD,2例HGD)出现发育异常,CIM中有1例(LGD)出现发育异常。两组在年龄、种族、发育异常患病率和发病率方面存在显著差异。与SSBO患者相比,CIM患者发育异常进展的时间明显更长。在5例SSBO和HGD患者中,1例在随访中发生了食管癌。在此期间,CIM患者未检测到HGD或癌症。
SSBO患者的发育异常风险显著高于CIM患者,表明两种潜在不同的临床过程。未来的研究应将SSBO与CIM区分开来,以增强对每个实体的病理生理学和恶性潜能的理解。